Great Lakes Advisors, LLC Ironwood Pharmaceuticals Inc Transaction History

Great Lakes Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$10.37 - $12.56 $404,191 - $489,551	-38,977 Reduced 5.58%	658,935 $6.93 Million
Q4 2022 Feb 09, 2023	SELL	$9.9 - $12.43 $157,340 - $197,549	-15,893 Reduced 2.23%	697,912 $8.65 Million
Q3 2022 Nov 09, 2022	SELL	$10.14 - $12.38 $231,628 - $282,796	-22,843 Reduced 3.1%	713,805 $7.4 Million
Q2 2022 Aug 09, 2022	SELL	$11.05 - $12.72 $121,980 - $140,416	-11,039 Reduced 1.48%	736,648 $8.49 Million
Q1 2022 May 06, 2022	SELL	$10.61 - $12.88 $1.98 Million - $2.4 Million	-186,368 Reduced 19.95%	747,687 $9.41 Million
Q4 2021 Feb 09, 2022	SELL	$10.86 - $13.95 $227,549 - $292,294	-20,953 Reduced 2.19%	934,055 $10.9 Million
Q3 2021 Nov 09, 2021	SELL	$11.92 - $13.92 $368,292 - $430,086	-30,897 Reduced 3.13%	955,008 $12.5 Million
Q2 2021 Aug 11, 2021	BUY	$10.16 - $13.11 $88,717 - $114,476	8,732 Added 0.89%	985,905 $12.7 Million
Q1 2021 May 03, 2021	BUY	$9.04 - $11.86 $8.83 Million - $11.6 Million	977,173 New	977,173 $10.9 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $539M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Great Lakes Advisors, LLC with notifications on news.